Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: A survival analysis

Scandinavian Journal of Rheumatology

Volumn 42, Issue 6, 2013, Pages 433-436

  Rodriguez Rodriguez, L ^a   Jover Jover, J A ^a   Fontsere, O ^a   Pena Blanco R C ^a   Leon L ^a   Fernandez Gutierrez B ^a   Abasolo L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE;

ADULT; AGED; ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SPAIN;

EID: 84887920856     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.785590     Document Type: Article

References (15)

1. Myasoedova E, Davis JM, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010;12:379-85
2. Hughes DA, Bagust A, Haycox A, Walley T. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: A review of the literature. Health Econ 2001;10:601-15
3. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66
4. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984-92
5. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research. Interpreting the evidence: Choosing between randomised and non-randomised studies. Br Med J 1999;319:312-15
6. Van Roon EN, Jansen TLTA, Mourad L, Houtman PM, Bruyn GAW, Griep EN, et al. Leflunomide in active rheumatoid arthritis: A prospective study in daily practice. Br J Clin Pharmacol 2004;57:790-7
7. Wolfe F, Michaud K, Stephenson B, Doyle J. Toward a definition and method of assessment of treatment failure and treatment effectiveness: The case of leflunomide versus methotrexate. J Rheumatol 2003;30:1725-32
8. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45:S66-76
9. Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, et al. Leflunomide use during the first 33 months after food and drug administration approval: Experience with a national cohort of 3,325 patients. Arthritis Rheum 2003;49:745-51
10. Hajidiacos NP, Robinson DB, Peschken CA. Leflunomide in clinical practice: Two-year population-based data with clinical validation. Arthritis Rheum 2002;46:S539
11. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8
12. Wolfe F, Stephenson B, Doyle J. RA patients remain on leflunomide as long as methotrexate in clinical practice: Accumulating evidence of long-term tolerability and effectiveness of leflunomide in RA. Arthritis Rheum 2001;44:S144
13. Jagoda JS, Rajapakse CNA. Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand. Int J Rheum Dis 2011;14:340-4
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
15. Alivernini S, Mazzotta D, Zoli A, Ferraccioli G. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: Retrospective analysis of safety and adherence to treatment. Drugs Aging 2009;26:395-402